Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIONA long-term open-label finerenone safety extension in pediatric chronic kidney disease with proteinuria
NL-OMON56223Phase 3Not yet recruiting
- Sponsor
- Bayer
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of finerenone in chronic kidney disease (CKD) and proteinuria, sponsored by Bayer. Primary endpoints: Treatment-emergent adverse events, Change in serum potassium and 1 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)proteinuria
Beyond the preview
Go deeper on NL-OMON56223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56223.